Skip to main content

Advertisement

SpringerLink
Log in

B-cell depletion in patients with rheumatoid arthritis refractant to multiple TNF blockers and the interleukin 1 receptor-antagonist anakinra

Good responses in an extreme negative selection

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

To evaluate the efficacy of Rituximab in a negatively selected patient cohort, with inadequate response to different disease modifying drugs (DMARDs) and to at least two biologicals. Fifteen patients with severe rheumatoid arthritis with inefficacy of an average of 5 DMARDS and 2.5 TNF antagonists were treated with Rituximab. Eight patients were ineffectively pretreated with Anakinra as well. The disease activity score (DAS28) and the morning stiffness served for assessment of the clinical response. For maintenance treatment different conventional DMARDs were used (4xMTX, 4xLeflunomide, 1xmycophenolate, 1xsirolimus, 1xhydroxychloroquine). At baseline visit the mean DAS 28 was 5.9. The mean duration of morning stiffness was 99.6 min. At month 6 the mean DAS28 was 3.95. Forty percent (6 patients) showed a good and 33% (5 patients) a moderate response. Morning stiffness improved to 43 min. In this negatively selected group of patients Rituximab was safe and effective.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Blumenauer B, Judd M, Cranney A, Burls A, Coyle D, Hochberg M, Tugwell P, Wells G (2003) Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev (4):CD004525

  2. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P et al (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 36(12):1681–1690

    Article  PubMed  CAS  Google Scholar 

  3. den Broeder A, van de Putte L, Rau R, Schattenkirchner M, Van Riel P, Sander O et al (2002) A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 29(11):2288–2298

    Google Scholar 

  4. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P et al (1998) Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41(12):2196–2204

    Article  PubMed  CAS  Google Scholar 

  5. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR et al (2004) Efficacy of B-Cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572–2581

    Article  PubMed  CAS  Google Scholar 

  6. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R et al (1994) Depletion of B cells in vivo b y a chimeric mouse human monoclonal antibody to CD20. Blood 83:435–445

    PubMed  CAS  Google Scholar 

  7. Edwards JC, Cambridge G (2005) Prospects for B-cell targeted therapy in autoimmune disease. Rheumatology 44:151–156

    Article  PubMed  CAS  Google Scholar 

  8. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A et al (2006) DANCER study group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Arthritis Rheum 54(5):1390–1400

    Article  PubMed  CAS  Google Scholar 

  9. Cohen SB et al (2005) Randomized Evaluation of long-term Efficacy of Rituximab in RA; REFLEX trial. Arthritis Rheum 52 (9) Abstract 1830 ACR 2005

  10. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324

    Article  PubMed  CAS  Google Scholar 

  11. van der Heijde DM, van ‘t Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, et al. (1990) Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 49:916–920

    Article  PubMed  Google Scholar 

  12. van Gestel AM, Haagsma CJ, van Riel PL (1998) Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 41(10):1845–1850

    Article  PubMed  Google Scholar 

  13. Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M et al (2003) Serological changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 48:2146–2154

    Article  PubMed  Google Scholar 

  14. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC (2006) Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment. Arthritis Rheum 54:723–732

    Article  PubMed  CAS  Google Scholar 

  15. Brulhart L, Ciurea A, Finckh A, Notter A, Waldburger JM, Kyburz D, Gabay C (2006) Efficacy of B cell depletion in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor agents: an open-label observational study. Ann Rheum Dis 65(9):1255–1257

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine II (Rheumatology, Immunology, Hematology, Oncology, Pulmology), University Hospital, Otfried-Mueller-Str. 10, 72076, Tuebingen, Germany

    J. C. Henes, L. Kanz & I. Koetter

  2. Private Practice, Stuttgart, Germany

    C. Richter

Authors
  1. J. C. Henes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Richter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Kanz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. Koetter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I. Koetter.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Henes, J.C., Richter, C., Kanz, L. et al. B-cell depletion in patients with rheumatoid arthritis refractant to multiple TNF blockers and the interleukin 1 receptor-antagonist anakinra . Rheumatol Int 28, 33–37 (2007). https://doi.org/10.1007/s00296-007-0376-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-007-0376-8

Keywords

Search

Navigation